Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
284
Zitationen
21
Autoren
2016
Jahr
Abstract
DNA derived from NSCLC tumors can be detected with high sensitivity in urine and plasma, enabling diagnostic detection and monitoring of therapeutic response from these noninvasive "liquid biopsy" samples.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 29.091 Zit.
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
1993 · 15.770 Zit.
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
2000 · 15.695 Zit.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 · 11.462 Zit.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · 9.967 Zit.
Autoren
- Karen L. Reckamp
- Vladislava O. Melnikova
- Chris Karlovich
- Lecia V. Sequist
- D. Ross Camidge
- Heather A. Wakelee
- M. Pérol
- Geoffrey R. Oxnard
- Karena Kosco
- Peter I. Croucher
- Errin Samuëlsz
- Cecile Rose T. Vibat
- Shiloh Guerrero
- Jennifer A. Geis
- David Berz
- Elaina Mann
- Shannon Matheny
- Lindsey Rolfe
- Mitch Raponi
- Mark G. Erlander
- Shirish M. Gadgeel